Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 11:44:34 UTC |
---|
Update Date | 2021-09-26 23:06:29 UTC |
---|
HMDB ID | HMDB0253331 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Ibritumomab tiuxetan |
---|
Description | 2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups. Based on a literature review very few articles have been published on 2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid. This compound has been identified in human blood as reported by (PMID: 31557052 ). Ibritumomab tiuxetan is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Ibritumomab tiuxetan is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 InChI=1S/C24H35N5O11/c1-15(28(11-20(32)33)12-21(34)35)8-27(10-19(30)31)9-18(29(13-22(36)37)14-23(38)39)7-16-3-5-17(6-4-16)26-24(40)25-2/h3-6,15,18H,7-14H2,1-2H3,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H,38,39)(H2,25,26,40) |
---|
Synonyms | Value | Source |
---|
2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetate | Generator |
|
---|
Chemical Formula | C24H35N5O11 |
---|
Average Molecular Weight | 569.568 |
---|
Monoisotopic Molecular Weight | 569.233306967 |
---|
IUPAC Name | 2-({2-[bis(carboxymethyl)amino]-3-{4-[(methylcarbamoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid |
---|
Traditional Name | ({2-[bis(carboxymethyl)amino]-3-{4-[(methylcarbamoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid |
---|
CAS Registry Number | Not Available |
---|
SMILES | CNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 |
---|
InChI Identifier | InChI=1S/C24H35N5O11/c1-15(28(11-20(32)33)12-21(34)35)8-27(10-19(30)31)9-18(29(13-22(36)37)14-23(38)39)7-16-3-5-17(6-4-16)26-24(40)25-2/h3-6,15,18H,7-14H2,1-2H3,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H,38,39)(H2,25,26,40) |
---|
InChI Key | RTQWWZBSTRGEAV-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Pentacarboxylic acids and derivatives |
---|
Direct Parent | Pentacarboxylic acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Pentacarboxylic acid or derivatives
- Alpha-amino acid
- Alpha-amino acid or derivatives
- Amphetamine or derivatives
- N-phenylurea
- Aralkylamine
- Benzenoid
- Monocyclic benzene moiety
- Amino acid or derivatives
- Amino acid
- Urea
- Tertiary aliphatic amine
- Tertiary amine
- Carboxylic acid
- Organic nitrogen compound
- Organonitrogen compound
- Carbonyl group
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Amine
- Organic oxygen compound
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Ibritumomab tiuxetan,1TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4845.5 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,1TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4067.7 | Standard non polar | 33892256 | Ibritumomab tiuxetan,1TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 7722.1 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4713.9 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3983.0 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 7175.2 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4580.1 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4062.8 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 6772.9 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4709.3 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3983.7 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 7177.1 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4707.7 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 3976.6 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 7167.1 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4448.6 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4010.5 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6358.2 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #13 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4597.5 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #13 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3934.3 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #13 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 6706.8 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4458.6 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4008.7 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 6343.8 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #16 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4607.4 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #16 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3939.6 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #16 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 6708.0 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4453.2 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4008.7 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 6357.7 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #3 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4594.7 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #3 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3936.1 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #3 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6707.5 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #6 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 4607.1 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #6 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 3938.5 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #6 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 6708.2 | Standard polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4600.0 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3944.1 | Standard non polar | 33892256 | Ibritumomab tiuxetan,3TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6720.1 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 4391.8 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 3966.8 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #11 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 5985.9 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4508.2 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3928.6 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6308.5 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #14 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4385.8 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #14 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3974.9 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #14 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6005.4 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4512.4 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3923.3 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #15 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 6291.0 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #17 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4387.0 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #17 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3970.2 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #17 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 5987.7 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 4391.0 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 3967.9 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #18 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O | 5986.6 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #2 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 4507.9 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #2 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 3923.1 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #2 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 6290.2 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #5 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4498.3 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #5 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3928.0 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #5 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 6307.7 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 4385.4 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 3972.0 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C | 5987.9 | Standard polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 4506.5 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 3927.1 | Standard non polar | 33892256 | Ibritumomab tiuxetan,4TMS,isomer #9 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C | 6307.4 | Standard polar | 33892256 | Ibritumomab tiuxetan,1TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 5061.1 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,1TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4226.3 | Standard non polar | 33892256 | Ibritumomab tiuxetan,1TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 7457.2 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O | 5160.8 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O | 4312.2 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #10 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O | 6880.0 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 5014.6 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4338.2 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #12 | CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 6604.0 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C | 5159.8 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C | 4314.2 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #4 | CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C | 6880.8 | Standard polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 5157.0 | Semi standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 4305.7 | Standard non polar | 33892256 | Ibritumomab tiuxetan,2TBDMS,isomer #7 | CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | 6870.9 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_5) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_8) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_9) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_11) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_5) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_7) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_8) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_10) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_12) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_14) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_17) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 10V, Positive-QTOF | splash10-0fki-0101490000-c5120fb01deefe11ea13 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 20V, Positive-QTOF | splash10-00di-0203690000-ce1ba21c6d250448ef07 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 40V, Positive-QTOF | splash10-0h6u-2902000000-cf452df02b42efbb8a10 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 10V, Negative-QTOF | splash10-014i-0000190000-f38e03beab61c949c76a | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 20V, Negative-QTOF | splash10-0596-0101890000-b1044e8538b1dfd1df00 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 40V, Negative-QTOF | splash10-0a7l-3716910000-87d84bad4a0cf50f46c0 | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|